Vanguard Group Inc. Cuts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

Vanguard Group Inc. lessened its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 18.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,747,760 shares of the company's stock after selling 2,435,792 shares during the quarter. Vanguard Group Inc. owned 4.81% of Sana Biotechnology worth $17,519,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. State Street Corp raised its position in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company's stock valued at $27,570,000 after purchasing an additional 269,274 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock valued at $13,175,000 after acquiring an additional 276,055 shares during the period. Corient Private Wealth LLC lifted its position in Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock worth $1,928,000 after acquiring an additional 730,699 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock valued at $1,722,000 after purchasing an additional 8,666 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Sana Biotechnology by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company's stock valued at $549,000 after purchasing an additional 9,905 shares during the period. Hedge funds and other institutional investors own 88.23% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SANA. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Tuesday, March 18th. HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research report on Tuesday, March 18th. Finally, Jefferies Financial Group began coverage on Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and an average target price of $10.80.

Sana Biotechnology Stock Up 8.8 %

Shares of SANA stock traded up $0.14 during mid-day trading on Tuesday, hitting $1.73. 1,897,709 shares of the stock were exchanged, compared to its average volume of 3,295,126. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $10.50. The company has a market cap of $389.29 million, a PE ratio of -1.24 and a beta of 1.78. The firm has a fifty day moving average of $2.20 and a 200 day moving average of $2.68.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Equities analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.